Resources
Principal content
New Mexico Gas Company on the block
Credit Suisse advising. by mergermarket
Ralls CFIUS block alters Sany’s future investment strategy in US
No security concerns raised in Ralls 2.0. by PaRR
Chiltern in talks to get new majority investor; hires Jefferies – sources
Investor with deep pockets sought to expand company’s service offerings. by BioPharm Insight
Lundbeck and Otsuka’s once-monthly schizophrenia drug advantageous though late market entry could hinder uptake
The new aripiprazole formulation is seen as more tolerable but less effective than available depot medications. by BioPharm Insight
HIV drugs to be uniquely shielded from generic pricing pressure in public payer scheme
Strict first-line generic, prior authorization mandates are unlikely. by BioPharm Insight
Novartis has fair claim to challenge German drug pricing law though weak case to protect diabetes drugs
Law wording leaves room for legal action though Novartis may fall short of victory. by BioPharm Insight
Asia investment grade bond volume looking flat for the year
Coupons and maturities to drive deals through the first half but returns will be lower. by dealReporter
Endo’s law suit against Impax for crush-proof Opana unlikely to reach settlement before May FDA ruling
Generic challengers to the pain drug can build around Endo’s patents regardless of the FDA ruling. by BioPharm Insight
Japan private equity landscape expected to see deal upswing in 2013
Political change and Japanese companies’ thirst for outbound growth expected to contribute to rise in private equity deals this year. by mergermarket
Best Buy buyout talks quiet
Pencils are down days ahead of bid deadline. by dealReporter